Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tineke J. Smilde has a total of 111 co-authors. Here are the top co-authors by number of shared publications:

  • Agnes J. van de Wouw

    Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands

    3 shared publications
  • D.J.A. Lobbezoo

    Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands; Máxima Medical Center, Eindhoven, P.O. Box 7777, 5500 MB Eindhoven, The Netherlands

    2 shared publications
  • F.P.J. Peters

    Zuyderland Medical Center, Sittard-Geleen, P.O. Box 5500, 6130 MB Sittard-Geleen, The Netherlands

    2 shared publications
  • Inge M. van Oort

    Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands

    2 shared publications
  • J.M.G. van Riel

    St Elisabeth Hospital, Tilburg, P.O. Box 90151, 5000 LC Tilburg, The Netherlands

    2 shared publications
  • M.W. Dercksen

    Máxima Medical Center, Eindhoven, P.O. Box 7777, 5500 MB Eindhoven, The Netherlands

    2 shared publications

Latest Publications

  • Open Access

    What is the appropriate timing for advance care planning according to patients and their relatives? A scoping review

    by Carolien Burghout, Sascha R. Bolt, Lenny M. W. Nahar-Van Venrooij, Tineke J. Smilde, Carin C. D. van der Rijt, Eveline J. M. Wouters

    Background: Advance care planning (ACP) is often initiated in the last phase of life. However, patients and relatives may need earlier conversations about their care preferences in the disease trajectory. Objective: To synthesize empirical research on the appropriate timing of ACP from the perspective of patients and relatives. Additionally, we investigated facilitators, challenges, and triggers related to that timing. Design and method: A scoping review was conducted using PubMed and CINAHL databases (up to April 2023; updated June 2025). Eligible studies focused on ACP timing from the perspectives of patients with cancer, heart or lung disease, and relatives. Two researchers independently screened papers and extracted data. Extracted data were clustered using thematic analysis. Results: In total, 29 papers were included. Both patients’ and relatives’ perspectives regarding the appropriate timing of initiating ACP varied widely and encompassed the entire continuum from healthy state, through illness, until the end of life. Timing related facilitating factors for initiating ACP were: clear information about prognosis, readiness, ACP as part of standard care, and clarity about who initiates ACP. Timing challenges were categorized as patient- (individual needs, coping, mutual protection), illness- (prognosis or illness related uncertainty) and professional-related (reluctance, time constraints). Additionally, patient-related (age, experiences in life) and trigger points in illness were identified. Conclusion: The wide range of perspectives regarding appropriate timing of ACP requires a personalized approach. Clinical triggers may provide guidance, though they are not universally applicable. Professionals should timely and regularly explore patients’ preferences and readiness for initiating ACP conversations.

  • Open Access

    Patients’ and relatives’ perspectives on the quality of end-of-Life care in advanced cancer: From the final months to bereavement

    by Moyke A. J. Versluis, Yvette M. van der Linden, Lobke van Leeuwen-Snoeks, Marieke H. J. van Den Beuken-Van Everdingen, Mathijs P. Hendriks, Ben E. E. M. van Den Borne, Dirkje Sommeijer, Jean-Paul A. van Basten, Annemieke van der Padt-Pruijsten, Alexander de Graeff, et al.

    Background: End-of-life care affects both patients with advanced cancer and their relatives but is often assessed from only one perspective, namely that of bereaved relatives. This study aimed to gain insight into the quality of care as experienced by patients with advanced cancer and their relatives. Methods: A total of 367 patients with stage IV cancer, 242 relatives and 163 bereaved relatives were included from a large prospective, longitudinal study (eQuiPe), which ran from November 2017 until March 2020. Patients and their relatives completed a questionnaire during the last 3 months of the patient’s life. Bereaved relatives completed a questionnaire within six months after the patient’s death. Results: At the end of life, patients reported a mean satisfaction with care score of 72/100 (SD 21), and relatives a mean score of 59/100 (SD 28) for the care they received themselves. Continuity with care, the extent to which the care received from different healthcare professionals was coordinated, was associated with higher satisfaction with care in patients (β 2.1, 95% CI 1.6–2.6). Bereaved relatives reported that most patients died peacefully (87%) and at home (73%). Most bereaved relatives (66%) were contacted by a healthcare professional after the patient’s death, but over half were not informed about grief (52%) or the available options for bereavement support (58%), with about 20% reporting they would have appreciated this. Conclusions: Quality of end-of-life care was generally perceived as good. This study highlights the importance of good continuity of care as it is associated with higher satisfaction with care in patients. Also, one-fifth of the bereaved relatives reported that they had not been informed about bereavement care despite desiring it, which emphasizes the need for better care for relatives before and after the patient’s death.

  • Open Access

    Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence

    by Dianne Bosch, Malou C. P. Kuppen, Metin Tascilar, Tineke J. Smilde, Peter F. A. Mulders, Carin A. Uyl-De Groot, Inge M. van Oort

    Background: Manual data collection is still the gold standard for disease-specific patient registries. However, CAPRI-3 uses text mining (an artificial intelligence (AI) technology) for patient identification and data collection. The aim of this study is to demonstrate the reliability and efficiency of this AI-driven approach. Methods: CAPRI-3 is an observational retrospective multicenter cohort registry on metastatic prostate cancer. We tested the patient-identification algorithm and automated data extraction through manual validation of the same patients in two pilots in 2019 and 2022. Results: Pilot one identified 2030 patients and pilot two 9464 patients. The negative predictive value of the algorithm was maximized to prevent false exclusions and reached 94.8%. The completeness and accuracy of the automated data extraction were 92.3% or higher, except for date fields and inaccessible data (images/pdf) (10–88.9%). Additional manual quality control took over 3 h less time per patient than the original fully manual CAPRI registry (105 vs. 300 min). Conclusions: The CAPRI-3 patient-identification algorithm is a sound replacement for excluding ineligible candidates. The AI-driven data extraction is largely accurate and complete, but manual quality control is needed for less reliable and inaccessible data. Overall, the AI-driven approach of the CAPRI-3 registry is reliable and timesaving.


  • Open Access

    The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands

    by Lisa M.C. van Hoogstraten, Lambertus A. Kiemeney, Richard P. Meijer, Geert J.L.H. van Leenders, Ben G.L. Vanneste, Luca Incrocci, Tineke J. Smilde, Sabine Siesling, J. Alfred Witjes, Katja K.H. Aben

    BACKGROUND: The COVID-19 pandemic has disrupted regular health care with potential consequences for non-COVID diseases like cancer. To ensure continuity of oncological care, guidelines were temporarily adapted. OBJECTIVE: To evaluate the impact of the COVID-19 outbreak on bladder cancer care in the Netherlands. METHODS: The number of bladder cancer (BC) diagnoses per month during 2020-2021 was compared to 2018-2019 based on preliminary data from the Netherlands Cancer Registry (NCR). Additionally, detailed data were retrieved from the NCR for the cohort diagnosed between March 1 st -May 31 st 2020 (first COVID wave) and 2018-2019 (reference cohort). BC diagnoses, changes in age and stage at diagnosis, and time to first-line treatment were compared between both periods. Changes in treatment were evaluated using logistic regression. RESULTS: During the first COVID wave (week 9–22), the number of BC diagnoses decreased by 14%, corresponding with approximately 300 diagnoses, but increased again in the second half of 2020. The decline was most pronounced from week 13 onwards in patients≥70 years and patients with non-muscle invasive BC. Patients with muscle-invasive disease were less likely to undergo a radical cystectomy (RC) in week 17–22 (OR = 0.62, 95% CI = 0.40–0.97). Shortly after the start of the outbreak, use of neoadjuvant chemotherapy decreased from 34% to 25% but this (non-significant) effect disappeared at the end of April. During the first wave, 5% more RCs were performed compared to previous years. Time from diagnosis to RC became 6 days shorter. Overall, a 7% reduction in RCs was observed in 2020. CONCLUSIONS: The number of BC diagnoses decreased steeply by 14% during the first COVID wave but increased again to pre-COVID levels by the end of 2020 (i.e. 600 diagnoses/month). Treatment-related changes remained limited and followed the adapted guidelines. Surgical volume was not compromised during the first wave. Altogether, the impact of the first COVID-19 outbreak on bladder cancer care in the Netherlands appears to be less pronounced than was reported for other solid tumors, both in the Netherlands and abroad. However, its impact on bladder cancer stage shift and long-term outcomes, as well as later pandemic waves remain so far unexamined.


  • Open Access

    RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

    by Emmy Boerrigter, Guillemette E. Benoist, Inge M. van Oort, Gerald W. Verhaegh, Anton F. J. de Haan, Onno van Hooij, Levi Groen, Frank Smit, Irma M. Oving, Pieter de Mol, et al.

    Treatment evaluation in metastatic castration-resistant prostate cancer is challenging. There is an urgent need for biomarkers to discriminate short-term survivors from long-term survivors, shortly after treatment initiation. Thereto, the added value of early RNA biomarkers on predicting progression-free survival (PFS) and overall survival (OS) were explored. The RNA biomarkers: KLK3 mRNA, miR-375, miR-3687, and NAALADL2-AS2 were measured in 93 patients with mCRPC, before and 1 month after start of first-line abiraterone acetate or enzalutamide treatment, in two prospective clinical trials. The added value of the biomarkers to standard clinical parameters in predicting PFS and OS was tested by Harell’s C-index. To test whether the biomarkers were independent markers of PFS and OS, multivariate Cox regression was used. The best prediction model for PFS and OS was formed by adding miR-375 and KLK3 (at baseline and 1 month) to standard clinical parameters. Baseline miR-375 and detectable KLK3 after 1 month of therapy were independently related to shorter PFS, which was not observed for OS. In conclusion, the addition of KLK3 and miR-375 (at baseline and 1 month) to standard clinical parameters resulted in the best prediction model for survival assessment.


  • Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer

    by Joost M. Blok, Harmke J. Groot, Eline H. Huele, Ronald de Wit, Simon Horenblas, Janine Nuver, Gerard Groenewegen, J.L.H. Ruud Bosch, J. Alfred Witjes, Jacqueline M. Tromp, et al.

    PURPOSE: Patients with testicular germ cell tumor (TGCT) are at increased risk of developing a contralateral TGCT (CTGCT). Although some studies suggest that prior treatment with platinum-based chemotherapy affects CTGCT risk, a relationship between CTGCT risk and platinum dose has not previously been assessed. We analyzed the association between the number of platinum-based chemotherapy cycles and CTGCT risk. PATIENTS AND METHODS: The risk of developing a metachronous CTGCT was evaluated in a nationwide cohort of 4,755 patients diagnosed with primary TGCT in the Netherlands between 1989 and 2007. Standardized incidence ratios were computed to compare CTGCT incidence with expected TGCT on the basis of TGCT incidence in the general population. The cumulative incidence of CTGCT was estimated in the presence of death as competing risk. The effect of treatment with platinum-based chemotherapy on CTGCT risk was assessed using multivariable Cox proportional hazards regression models. RESULTS: CTGCT was diagnosed in 136 patients (standardized incidence ratio, 14.6; 95% CI, 12.2 to 17.2). The cumulative incidence increased up to 20 years after primary diagnosis, reaching 3.4% (95% CI, 2.8% to 4.0%) after 20 years of follow up. The risk of developing a CTGCT decreased with age (hazard ratio [HR], 0.93; 95% CI, 0.90 to 0.96), was lower after nonseminomatous germ cell tumor (HR, 0.58; 95% CI, 0.35 to 0.96) and decreased with every additional cycle of chemotherapy (HRper cycle, 0.74; 95% CI, 0.64 to 0.85). CONCLUSION: Approximately one in every 30 survivors of TGCT will develop a CTGCT, with CTGCT incidence increasing up to 20 years after a primary TGCT. Treatment with platinum-based chemotherapy shows a dose-dependent inverse association with CTGCT risk.


  • Open Access

    Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study

    by Julia E.C. Van Steenhoven, Anne Kuijer, Paul J. Van Diest, Joost M. Van Gorp, Marieke Straver, Sjoerd G. Elias, Jelle Wesseling, Emiel Rutgers, Johanna N.H. Timmer-Bonte, Peter Nieboer, et al.

    In this study, in estrogen receptor positive (ER+) early stage breast cancer patients who were considered candidates for 70-gene signature (70-GS, “MammaPrint”) use, we compared molecular subtyping (MS) based on the previously validated 80-gene signature (80-GS, “BluePrint”) versus surrogate pathological subtyping (PS). Between 1 January 2013 and 31 December 2015, 595 clinical intermediate risk ER+ early stage breast cancer patients were enrolled. Hormone receptor (HR) and HER2 receptor status were determined by conventional pathology using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). Ki67 was assessed in a subset of patients. The overall concordance between PS and MS for luminal type cancers (A and B together) was 98%. The concordance between PS and MS for luminal A and luminal B type cancers based on the Bloom Richardson histological grade (BR) (n = 586) or Ki67 (n = 185) was low: 64% (Kappa 0.20 [95% CI 0.11–0.28]) and 65% (Kappa 0.22 [95% CI 0.062–0.37]), respectively. In this prospective study (NCT02209857) of a selection of ER+ and predominantly HER2− early-stage breast cancer patients, the additional ability of the 80-GS to distinguish between luminal, HER2-type and basal-like cancers was inherently very limited. The distinction of luminal-type tumors into A and B according to Ki67 status or BR grade versus the 70-GS revealed poor concordance.


  • Open Access

    Decision aids for second-line palliative chemotherapy: a randomised phase II multicentre trial

    by Linda J. M. Oostendorp, Petronella B. Ottevanger, A. Rogier T. Donders, Agnes J. van de Wouw, Ivonne J. H. Schoenaker, Tineke J. Smilde, Winette T. A. van der Graaf, Peep F. M. Stalmeier

    There is increasing recognition of the delicate balance between the modest benefits of palliative chemotherapy and the burden of treatment. Decision aids (DAs) can potentially help patients with advanced cancer with these difficult treatment decisions, but providing detailed information could have an adverse impact on patients' well-being. The objective of this randomised phase II study was to evaluate the safety and efficacy of DAs for patients with advanced cancer considering second-line chemotherapy. Patients with advanced breast or colorectal cancer considering second-line treatment were randomly assigned to usual care (control group) or usual care plus a DA (intervention group) in a 1:2 ratio. A nurse offered a DA with information on adverse events, tumour response and survival. Outcome measures included patient-reported well-being (primary outcome: anxiety) and quality of the decision-making process and the resulting choice. Of 128 patients randomised, 45 were assigned to the control group and 83 to the intervention group. Median age was 62 years (range 32-81), 63% were female, and 73% had colorectal cancer. The large majority of patients preferred treatment with chemotherapy (87%) and subsequently commenced treatment with chemotherapy (86%). No adverse impact on patients' well-being was found and nurses reported that consultations in which the DAs were offered went well. Being offered the DA was associated with stronger treatment preferences (3.0 vs. 2.5; p=0.030) and increased subjective knowledge (6.7 vs. 6.3; p=0.022). Objective knowledge, risk perception and perceived involvement were comparable between the groups. DAs containing detailed risk information on second-line palliative treatment could be delivered to patients with advanced cancer without having an adverse impact on patient well-being. Surprisingly, the DAs only marginally improved the quality of the decision-making process. The effectiveness of DAs for palliative treatment decisions needs further exploration. Netherlands Trial Registry (NTR): NTR1113 (registered on 2 November 2007)


  • Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium

    by R.J.W. van Kampen, B.L.T. Ramaekers, D.J.A. Lobbezoo, M. de Boer, M.W. Dercksen, F. van Den Berkmortel, T.J. Smilde, A.J. van de Wouw, F.P.J. Peters, J.M.G. van Riel, et al.


  • A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium

    by R.J.W. van Kampen, D.J.A. Lobbezoo, M. de Boer, M.W. Dercksen, A.C. Voogd, F. van Den Berkmortel, T.J. Smilde, A.J. van de Wouw, F.P.J. Peters, J.M.G. van Riel, et al.